Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases.
about
Regulation of intraocular pressure by soluble and membrane guanylate cyclases and their role in glaucomaAdvances in the management of constipation-predominant irritable bowel syndrome: the role of linaclotideCatalytically Active Guanylyl Cyclase B Requires Endoplasmic Reticulum-mediated Glycosylation, and Mutations That Inhibit This Process Cause DwarfismThe Concise Guide to PHARMACOLOGY 2013/14: catalytic receptors.BNP and Heart Failure: Preclinical and Clinical Trial Data.Linaclotide: A new drug for the treatment of chronic constipation and irritable bowel syndrome with constipationGuanylyl cyclase (GC)-A and GC-B activities in ventricles and cardiomyocytes from failed and non-failed human hearts: GC-A is inactive in the failed cardiomyocyte.Advances in targeting cyclic nucleotide phosphodiesterasesA functional screen provides evidence for a conserved, regulatory, juxtamembrane phosphorylation site in guanylyl cyclase a and B.Dephosphorylation and inactivation of NPR2 guanylyl cyclase in granulosa cells contributes to the LH-induced decrease in cGMP that causes resumption of meiosis in rat oocytes.Cell surface protein disulfide isomerase regulates natriuretic peptide generation of cyclic guanosine monophosphate.The indolocarbazole, Gö6976, inhibits guanylyl cyclase-A and -B.ATP potentiates competitive inhibition of guanylyl cyclase A and B by the staurosporine analog, Gö6976: reciprocal regulation of ATP and GTP bindingGuanylyl cyclases A and B are asymmetric dimers that are allosterically activated by ATP binding to the catalytic domain.Natriuretic peptide metabolism, clearance and degradation.Luteinizing hormone reduces the activity of the NPR2 guanylyl cyclase in mouse ovarian follicles, contributing to the cyclic GMP decrease that promotes resumption of meiosis in oocytes.The Gyc76C Receptor Guanylyl Cyclase and the Foraging cGMP-Dependent Kinase Regulate Extracellular Matrix Organization and BMP Signaling in the Developing Wing of Drosophila melanogaster.Linaclotide (Linzess) for Irritable Bowel syndrome With Constipation and For Chronic Idiopathic ConstipationDendroaspis natriuretic peptide and the designer natriuretic peptide, CD-NP, are resistant to proteolytic inactivationGuanylyl cyclase structure, function and regulation.Dephosphorylation of juxtamembrane serines and threonines of the NPR2 guanylyl cyclase is required for rapid resumption of oocyte meiosis in response to luteinizing hormone.Novel MicroRNA Regulators of Atrial Natriuretic Peptide Production.Luteinizing Hormone Causes Phosphorylation and Activation of the cGMP Phosphodiesterase PDE5 in Rat Ovarian Follicles, Contributing, Together with PDE1 Activity, to the Resumption of MeiosisPhylogenetic investigation of Peptide hormone and growth factor receptors in five dipteran genomes.Optimizing the Use of Linaclotide in Patients with Constipation-Predominant Irritable Bowel Syndrome: An Expert Consensus Report.Linaclotide: a novel approach to the treatment of irritable bowel syndrome.Allosteric regulation of nucleotidyl cyclases: an emerging pharmacological target.Novel approaches and opportunities for cardioprotective signaling through 3',5'-cyclic guanosine monophosphate manipulation.Cyclic nucleotide phosphodiesterases (PDEs): coincidence detectors acting to spatially and temporally integrate cyclic nucleotide and non-cyclic nucleotide signals.New pharmacological treatment options for chronic constipation.Comparison of moonlighting guanylate cyclases: roles in signal direction?Natriuretic hormones in brain function.Mechanisms of renal hyporesponsiveness to BNP in heart failure.From bedside to bench--meeting report of the 7th International Conference on cGMP "cGMP: generators, effectors and therapeutic implications" in Trier, Germany, from June 19th to 21st 2015.Novel pharmacological therapies for irritable bowel syndrome.Brain natriuretic peptide constitutively downregulates P2X3 receptors by controlling their phosphorylation state and membrane localizationB-type natriuretic peptide and heart failure: what can we learn from clinical trials?Guanylyl cyclase C and guanylin reduce fat droplet accumulation in cattle mesenteric adipose tissue.Antibody tracking demonstrates cell type-specific and ligand-independent internalization of guanylyl cyclase a and natriuretic peptide receptor C.A Glial K/Cl Transporter Controls Neuronal Receptive Ending Shape by Chloride Inhibition of an rGC.
P2860
Q26861763-8AFBDAD3-2909-4FF7-A389-42D57150C952Q26865304-4CDD237D-5E92-4028-8DC0-097E7314DBF2Q28116378-757C502E-EEE5-43C1-AB9B-45F52A90CAD7Q30486741-E1826330-D310-4425-9CF6-384042A97804Q30909922-F9340A80-0827-4F88-BDC7-9177002A41E6Q33695487-B091A6CE-25B9-4047-9950-E03CB6594EF0Q33792340-BABDE860-0C8D-43EB-A54B-A21431760F8DQ34139490-0D6C5126-C7D4-47FD-A4C0-24D7726CFC6CQ34270975-0A520F70-3DB1-4BF5-8F20-97B44901DE45Q34341855-E3F4D85D-3021-4041-8A03-D3A8B27042C4Q34565711-EA77AB20-0401-4816-9218-71ABE5EB5B18Q35287220-2C74648F-6920-4344-B3C3-A86035F1F47AQ35310662-73E6CFF0-D559-4B03-BBFB-948615F5DFC4Q35543592-1E9593A5-3CDD-411C-8C38-9C4287DBD555Q35831469-594B20BE-5924-4F57-A9AF-7969FDBE0E47Q35981008-4CC107DA-F5A1-4E01-BB1B-3721427F9846Q36126757-0E681DBE-2D16-4BE2-8C13-7CBC8E227D7AQ36801233-F4059C45-A323-4EDA-BD54-30F350F79BB0Q36865781-0A16D777-3408-4169-9E73-B099ABF0E2B0Q36867727-515E15D0-7610-4418-BE50-429B96F135BEQ36882363-2A04D929-536D-46F1-AADE-2EE92D711111Q37073172-C7F6F59F-6673-4DB9-846B-F4E69B4A3F58Q37082085-AF071A2F-C05F-45F9-B67E-A34CF9B7A59EQ37394215-DA227E05-8974-427E-AF0F-EA4F1EAB1B32Q37699695-6FE1AED8-3139-47A4-9962-FA0582FB58DBQ37951907-223E1EED-6F84-46B5-A279-BFE50D1F8485Q38040779-A7110331-7744-4A33-AA0C-C39D85AB37F9Q38191314-FA1DD16B-5C35-431C-B254-19B995268B3DQ38197306-4DF61ED5-2140-4F3B-806A-3561479A600FQ38198743-38F6BE87-225A-4EC1-865B-5A0268B9DBE4Q38268490-8309C005-788C-4D30-A540-0734B7FEC35EQ38288274-F342CBF3-AE4E-4933-9A40-8A396B5A104CQ38424318-865082A2-E32D-4E2B-B552-02FFA147E94FQ38612665-84EC18AE-4CE9-4F07-ADC5-324D1E541F09Q38747166-E4AA1929-2C19-4D87-8508-F637D4FCC992Q38942004-F05541CF-6F2A-48DC-9860-3140412AA786Q39007435-48BFABFD-4CDA-410F-96DB-AF73D80B7970Q39430494-A3BB004E-6036-4104-95C5-6BC5AE7C6A47Q39557637-CA2C8081-73E9-4D2B-A181-3ADFCE1851D5Q39756737-E9D5E846-0123-405A-8F8E-3151B79C9D2C
P2860
Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases.
@en
type
label
Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases.
@en
prefLabel
Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases.
@en
P2860
P1476
Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases.
@en
P2093
Lincoln R Potter
P2860
P356
10.1016/J.PHARMTHERA.2010.12.005
P577
2010-12-24T00:00:00Z